Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

Jared Weiss; Jerome Goldschmidt; Zoran Andric; Konstantin H. Dragnev; Chad Gwaltney; Konstantina Skaltsa; Yili Pritchett; Joyce M. Antal; Shannon R. Morris; Davey Daniel

doi:10.1016/J.CLLC.2021.03.010

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

Jared Weiss
, Jerome Goldschmidt
, Zoran Andric
, Konstantin H. Dragnev
, Chad Gwaltney
, Konstantina Skaltsa
, Yili Pritchett
, Joyce M. Antal
, Shannon R. Morris
, Davey Daniel

University of North Carolina at Chapel Hill
Blue Ridge Cancer Care, US Oncology Research, Blacksburg, VA.
University Hospital Medical Center Bezanijska Kosa, Bezanijska Kosa, Belgrade, Serbia.
Dartmouth-Hitchcock Medical Center
Gwaltney Consulting, Westerly, RI.
IQVIA Consulting Services, Barcelona, Spain.
Research Triangle Park
Sarah Cannon Research Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Lung Cancer
DOIs	https://doi.org/10.1016/J.CLLC.2021.03.010
State	Published - Mar 26 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1016/J.CLLC.2021.03.010License: Unspecified

Cite this

Weiss, J., Goldschmidt, J., Andric, Z., Dragnev, K. H., Gwaltney, C., Skaltsa, K., Pritchett, Y., Antal, J. M., Morris, S. R., & Daniel, D. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer. https://doi.org/10.1016/J.CLLC.2021.03.010

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. / Weiss, Jared; Goldschmidt, Jerome; Andric, Zoran et al.
In: Clinical Lung Cancer, 26.03.2021.

Research output: Contribution to journal › Article › peer-review

Weiss, J, Goldschmidt, J, Andric, Z, Dragnev, KH, Gwaltney, C, Skaltsa, K, Pritchett, Y, Antal, JM, Morris, SR & Daniel, D 2021, 'Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.', Clinical Lung Cancer. https://doi.org/10.1016/J.CLLC.2021.03.010

Weiss J, Goldschmidt J, Andric Z, Dragnev KH, Gwaltney C, Skaltsa K et al. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer. 2021 Mar 26. doi: 10.1016/J.CLLC.2021.03.010

@article{b49b39722e994648a35d9b124f620408,

title = "Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.",

author = "Jared Weiss and Jerome Goldschmidt and Zoran Andric and Dragnev, \{Konstantin H.\} and Chad Gwaltney and Konstantina Skaltsa and Yili Pritchett and Antal, \{Joyce M.\} and Morris, \{Shannon R.\} and Davey Daniel",

note = "Administering trilaciclib prior to chemotherapy resulted in clinically meaningful reductions in CIM and its consequences and improved patient HRQoL, with no impact on the antitumor efficacy of three individual chemotherapy regimens used in the first- or second-/third-line treatment of ES-SCLC.",

year = "2021",

month = mar,

day = "26",

doi = "10.1016/J.CLLC.2021.03.010",

language = "American English",

journal = "Clinical Lung Cancer",

issn = "1938-0690",

publisher = "Elsevier",

}

TY - JOUR

T1 - Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

AU - Weiss, Jared

AU - Goldschmidt, Jerome

AU - Andric, Zoran

AU - Dragnev, Konstantin H.

AU - Gwaltney, Chad

AU - Skaltsa, Konstantina

AU - Pritchett, Yili

AU - Antal, Joyce M.

AU - Morris, Shannon R.

AU - Daniel, Davey

N1 - Administering trilaciclib prior to chemotherapy resulted in clinically meaningful reductions in CIM and its consequences and improved patient HRQoL, with no impact on the antitumor efficacy of three individual chemotherapy regimens used in the first- or second-/third-line treatment of ES-SCLC.

PY - 2021/3/26

Y1 - 2021/3/26

UR - https://pubmed.ncbi.nlm.nih.gov/33895103/

U2 - 10.1016/J.CLLC.2021.03.010

DO - 10.1016/J.CLLC.2021.03.010

M3 - Article

SN - 1938-0690

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

ER -

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

Disciplines

Access to Document

Other files and links

Cite this